Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG has demonstrated a strong commitment to advancing its clinical pipeline, reflected in increased research and development expenses, which surged to CHF 52.1 million for the fiscal year, significantly higher than the previous CHF 29.2 million. The company has achieved promising clinical results for its therapies, particularly OCS-05, which indicated statistically significant improvements in visual function for patients treated, suggesting strong potential for its product candidates in the market. Additionally, the firm's estimated market value has risen to $1.41 billion, providing a solid financial foundation and enhancing its attractiveness to investors.

Bears say

Oculis Holding AG is facing significant challenges that contribute to a negative outlook, primarily due to potential delays in clinical development and regulatory approvals, which could result in protracted development timelines and escalating costs. Additionally, the company is at risk from market competition, with both existing and emerging therapies vying for similar indications, thereby threatening its market penetration and pricing strategies. Furthermore, Oculis reported a substantial net loss of CHF 85.8 million in 2024, indicating financial strain that may hinder its operational capabilities and ability to advance key product candidates.

OCS has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 6 analysts, OCS has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.